Synthesis and antitumor activity of new platinum complexes

Piperazine-Bridged Homodinuclear Transition Metal Complexes

Piperazine-bridged transition metal complexes of the type [M(etdtc)]2ppzdtc and [M1(etdtc)2]2ppzdtc [where M = Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and Hg(II), M1 = Cr(III), Fe(III), etdtc = (S2NC5H10) and ppzdtc = [S2C(NCH2CH2)2CS2] have been synthesised and characterised by elemental analyses, magnetic susceptibility measurements, TGA/DSC, IR and electronic spectroscopy and conductivity measurements. The presence of only one (C–S) stretching frequency at around 1000 cm−1 supports symmetrical bonding of the dithiocarbamato-moiety. The low molar conductance value of the complexes in DMSO at 25 °C indicates their non-electrolytic behaviour. Thermogravimetric analysis showed only two-step, simple pyrolysis. The decomposition is generally exothermic, leading to the formation of metal sulfide as the final product. The complexes of divalent metal ions appear to be tetrahedral, excepting Cu(II) and Ni(II) which are square-planar, while those of trivalent metal ions are octahedral, which is also corroborated from their electronic spectra and magnetic moment data.

Synthesis, in vitro cytotoxicity, and structure-activity relationships (SAR) of multidentate oxidovanadium(iv) complexes as anticancer agents

Multidentate oxidovanadium(iv) complexes with different geometric configurations [VO(ox)(bpy)(H2O)] 1, [VO(ox)(phen)(H2O)] 2, [VO(ida)(bpy)]·2H2O 3, (phen)[VO(ida)(phen)]·4H2O 4, and (Hphen)[VO(H2O)(nta)]·2H2O 5 [ox = oxalic acid, bpy = 2,2'-bipyridine, phen = 1,10-phenanthroline, ida = iminodiacetic acid, nta = nitrilotriacetic acid] have been obtained from the reactions of oxidovanadium sulfate or vanadium pentoxide with oxalates, amino-polycarboxylates and N-heterocyclic ligands in neutral solution by the hydrothermal method, and have been fully characterized by elemental, thermogravimetric analyses and single crystal X-ray diffraction, as well as a wide range of spectroscopic techniques such as FT-IR, UV/Vis, NMR, ESI-MS. The anti-tumor properties of oxidovanadium compounds 1-5 were further evaluated in human HepG2 and SMMC-7721 hepatocellular carcinoma cell lines in vitro. The profiles of cytotoxicity, cell cycle distribution, as well as cell apoptosis upon test compound exposure, were determined by MTT and flow cytometry assays. Compound 2 exhibited a much higher anti-tumor activity than others. The IC50 values of 2 were 5.34 ± 0.034 μM and 29.07 ± 0.017 μM in SMMC-7721 and HepG2 cells after 48 h treatment, respectively. Furthermore, compound 2 could significantly arrest the cell cycle in the S and G2/M phases and further induce cell apoptosis in a dose-dependent manner. The structure-activity relationship (SAR) studies revealed that structural elements, for example, metal components, variations of coordination mode, labile water molecules, chelated ligands etc., probably exert an essential cooperative effect on the antitumor activity. In short, these findings not only provide an accessible model system to exploit V-based complexes as potential simple, safe and effective multifunctional antitumor agents, but also open up a rational approach to shed new light on the selection and optimization of ideal drug candidates.

An asymmetric binuclear zinc(ii) complex with mixed iminodiacetate and phenanthroline ligands: synthesis, characterization, structural conversion and anticancer properties

A water-soluble asymmetric binuclear zinc(ii) complex with mixed iminodiacetate and 1,10-phenanthroline ligands exhibited promising anticancer activity and low toxicity, suggesting potential as a chemotherapeutic agent.

Selective synthesis of cis- and trans-[(NHCMe)2PtCl2] and [NHCMePt(cod)Cl][NHCMePtCl3] using NHCMeSiCl4

NHC^MeSiCl₄ was used to selectively synthesise cis and trans-[(NHC^Me)₂PtCl₂], as well as [NHC^MePt(cod)Cl][NHC^MePtCl₃], which revealed the first ever N-heterocyclic carbene analogue of the Cossa's salt anion.

Novel thiocyanato complexes with potent cytotoxic and antimicrobial properties

The aim of the present study was to assess the cytotoxic and antimicrobial properties of seven new thiocyanato complexes: Ni(C9H11N2O)(SCN), Cu(C9H11N2O)(SCN), Pd(C9H11N2O)(SCN), Pt(C9H11N2O) (SCN), K[Ti(C9H11N2O)(SCN)3], Au(C9H11N2O)(SCN), and K[V(O)(C9H11N2O)(SCN)] (T1-T7, respectively). All the complexes showed toxicity against brine shrimp nauplii (Artemia salina L.). The titanium-based complex, T5, exhibited potent toxicity, with a lethal concentration 50% (the concentration of test compound that kills 50% of A. salina) value of 1.59 μg mL−1. These new complexes also exhibited promising antibacterial and antifungal properties. A macrodilution technique was used to estimate the minimum inhibitory concentrations of the seven bioactive complexes. Minimum inhibitory concentrations were found to be 8–64 μg mL−1 against the tested bacterial species.

In vitro antimicrobial and cytotoxic activities of ferrocene derivative compounds

The aim of the present study was to investigate the biocidal activity of four new ferrocene derivative based coordination complexes, [1,2,3-trithia-/3/-ferrocenophane, C1]; [disodium-1,1'-ferrocenedithiolate, C2]; [1,1'-(ferrocene-1,1'-diyl)-diethanol, C3]; [ferrocenyl(ethyl-phenyl)-methanol, C4]; against microbes (bacteria and fungi) and brine shrimp (Artemia salina Lech.) nauplii. C2 showed modest antibacterial activity at the concentration of 200 microg disc(-1) and gave its Minimum Inhibitory Concentration values at 32-64 microg mL(-1) against the tested bacteria. These complexes gave comparatively better antibacterial activity against the Gram-positives than the Gram-negatives. C3, C1 and C4 showed moderate antifungal activity at concentration of 200 microg disc(-1). Brine shrimp eggs were hatched in artificial sea water and exposed to the complexes. Median lethal concentration (LC50) values were calculated. Both complexes showed toxicity against brine shrimp but complex C3 explored its potent cytotoxicity having LC50 values at 6.031 microg mL(-1) (ppm).

Synthesis and in vitro cytotoxicity of novel hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes

Twenty-six new hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes having a seven-membered ring structure between a bidentate carrier ligand and a platinum atom have been synthesized and most of them were evaluated for their in vitro cytotoxicity toward A549 human non-small cell lung carcinoma and HCT-116 human colon cancer cell lines. The cytotoxicities of platinum complexes are related to the nature of the carrier ligand and leaving group. Complex 5'b, viz. cis-dichloro[(2R)-ethoxy-1,4-butanediamine] platinum (II), exhibits the greatest potency among those 21 tested platinum complexes in both cell lines.

Luminescent Platinum(II) Dimers with a Cyclometallating Aryldiamine Ligand

Triflate salts of three (Pt(pip2NCN))2(mu-L)2+ (pip2NCNH = 1,3-bis(piperidylmethyl)benzene) dimers bridged by a series of nitrogen-donor ligands (L = pyrazine (pyz), 1,2-bis(4-pyridyl)ethane (bpa), trans-1,2-bis(4-pyridyl)ethylene (bpe)) are reported. These complexes have been fully characterized by 1H NMR spectroscopy and elemental analysis. The X-ray crystal structures of [(Pt(pip2NCN))2(mu-pyz)](CF3SO3)2 and [(Pt(pip2NCN))2(mu-bpe)](CF3SO3)2 x 2CH2Cl2 are reported. [(Pt(pip2NCN))2(mu-pyz)](CF3SO3)2: triclinic, P, a = 12.5240(5) A, b = 14.1570(6) A, c = 14.2928(6) A, alpha = 106.458(1) degrees , beta = 92.527(1) degrees , gamma = 106.880(1) degrees , V = 2303.46(17) A(3), Z = 2. [(Pt(pip2NCN))2(mu-bpe)](CF3SO3)2 x 2CH2Cl2: monoclinic, P21/c, a = 10.1288(6) A, b = 16.3346(9) A, c = 17.4764(10) A, beta = 90.882(2) degrees , V = 2891.1(3) A3, Z = 2. These structures and solution measurements provide evidence for the strong trans-directing properties of the pip2NCN- ligand. The electronic structures of these complexes and those of the 4,4'-bipyridine (bpy) dimer, (Pt(pip2NCN))2(mu-bpy)2+, also have been investigated by UV-visible absorption and emission spectroscopies, as well as cyclic voltammetry. The accumulated data indicate that variations in the bridging ligands provide remarkable control over the electronic structures and photophysics of these complexes. Notably, the bpa dimer exhibits a broad, low-energy emission from a metal-centered 3LF excited state, whereas the bpe and bpy dimers exhibit structured emission from a lowest pyridyl-centered 3(pi-pi*) excited state. In contrast, the pyz dimer exhibits remarkably intense yellow emission tentatively assigned to a triplet metal-to-ligand charge-transfer excited state.

Evaluation of in Vitro Antimicrobial and in Vivo Cytotoxic Properties of Some Novel Titanium-Based Coordination Complexes

The aim of the present study was to determine the antimicrobial and cytotoxic activities of eight novel titanium(III) based coordination complexes [Ti(Pht)(2)(DL-serine)(2), S(1)], [Ti(Pht)(2)(glycine)(2), S(2))], [Ti(Pht)(2)(cystine)(2), S(3)], [Ti(Pht)(2)(DL-leucine)(2), S(4)], [Ti(Suc)(2)(L-leucine)(2), S(5)], [Ti(Suc)(2)(cystine)(2), S(6)], [Ti(Suc)(2)(cystein)(2), S(7)] and [Ti(Suc)(2)(DL-serine)(2), S(8)] against several gram-positive and -negative bacteria, fungi and brine shrimp nauplii. The investigation showed that almost all of the complexes were moderately active against tested bacteria and fungi at high concentration (200 microg/disc) compared with the standard antibiotic, amoxicillin and the antifungal agent, nystatin. In vivo lethality bioassay experiment showed that only S(7) and S(8) among the complexes had better cytotoxic effect than standard gallic acid. The LC(50) values of these two complexes were found to be 1.00 and 1.21 microg/ml, respectively. Thus the results suggest that only two complexes (S(7), S(8)) among the titanium(III) based coordination complexes show the anticancer properties comparable to the standard cytotoxic agent, and further studies of these two complexes may be helpful for their clinical implication.

A novel approach to preparing water soluble prodrug forms of cisplatin analogues bearing chelating diamines

A novel method for creating water soluble prodrugs of cisplatin analogues bearing chelating diamines is introduced. When 2-(amino-methyl)aniline is reacted with K2PtCl4 between a pH of 6 and 7, the neutral chelated complex [2-(aminomethyl)aniline)dichloroplatinum(II) (1) is isolated. On the other hand, when the complexation occurs under acidic conditions (i.e. pH 3), the zwitterionic, "open-ring" form [2-(ammonio-methyl)aniline-N1]trichloroplatinate(II) (2) is obtained, whereby only the aniline nitrogen is coordinated to platinum. Compound 2 has a solubility of 10 mM in acidic aqueous medium; that is ca. 20 times greater than that of 1. However, 2 rapidly converts to compound 1 at physiologic pH; thus 2 functions as a water soluble prodrug of 1. Both 1 and 2 are equally effective at halting the growth of three different human cancer cell lines in vitro, indicating that the prodrug is quantitatively converted to the parent drug in a complex, biologically relevant medium. In animal experiments, the prodrug form, when given at a dose of 25 mumol/kg three times a week for 6 weeks, significantly inhibits the growth of the MXT (M3.2) mammary tumor in BDF mice while the same dose of the parent drug has no antitumor activity.

Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II)

The emergence of drug resistance during tumor chemotherapy is one of the main problems associated with cancer treatment, particularly with cisplatin (cis-DDP). In the hope of overcoming this problem, various cis-DDP-derived compounds have been synthesized, and their pharmacological activity was compared with that of cis-DDP. In this paper we report on studies on the cytotoxic activity induced by cis-diamminechloro-[2-(diethylamino)ethyl-4-aminobenzoate, N4]- chlorideplatinum(II) monohydrochloride monohydrate (DPR), a new complex of platinum containing procaine. All experiments were carried out on murine leukemic cells, which were either sensitive (L1210) or resistant (L1210/DDP) to cis-DDP. A tetrazolium dye (MTT) assay conducted 5 days after a 2-h exposure of cells to both drugs was utilized to determine the resistance factor (RF) of L1210/DDP cells as compared with the sensitive wild-type cells. Drug accumulation and efflux, together with the amount of platinum bound to DNA, were also investigated. The activity of DPR on sensitive cells was not significantly different from that of cis-DDP. Conversely, DPR was 4.3 times more effective than cis-DDP on resistant cells. A decreased drug accumulation is one of the mechanisms of resistance to cis-DDP of L1210/DDP cells. However, DPR accumulation was not significantly different in sensitive and resistant L1210 cells. Under culture conditions that yielded similar intracellular platinum concentrations, treatment with DPR produced significantly greater DNA platination than did treatment with cis-DDP in both cell lines. No difference in efflux was observed between L1210 and L1210/DDP cells exposed to either cis-DDP or DPR. Our results show that in parental cells, DPR is as potent as cis-DDP on a molar basis, and it is also minimally cross-resistant with cis-DDP in L1210/DDP cells. A direct implication of our results is that DPR could be useful in those human tumors showing a mechanism of resistance similar to that of L1210/DDP cells.

Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells

We have examined the cytotoxicity and accumulation of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)platinum(II) monohydrate (DWA2114R) in parent and cisplatin-resistant mouse P388 leukemia cells (P388 and P388/DDP), in comparison with those of cisplatin (CDDP) and carboplatin (CBDCA). The degrees of resistance to CDDP and CBDCA, expressed as the ratio of IC50 for P388/DDP cells to IC50 for P388 cells, were 75-33 and 100-27, respectively, under the conditions of 2-24 h exposure to each drug at a density of 10(6) cells/ml. The corresponding values (25-7) for DWA2114R were relatively low. Accumulations of CDDP and CBDCA were reduced in P388/DDP cells; however, no reduction in accumulation of DWA2114R was observed at various exposure periods and concentrations of the drugs. The accumulations of CDDP in P388 and P388/DDP cells at drug concentrations corresponding to the IC50 values for drug exposure periods of 2-24 h were 0.41-0.97 and 13.1-33.7 ng Pt/10(7) cells, respectively, suggesting that an intracellular mechanism of resistance against CDDP could be activated in P388/DDP cells. P388/DDP cells also showed relatively low resistance to DWA2114R via this mechanism in comparison with CDDP and CBDCA. From the relationship between structure and activity of several Pt-complexes, these different properties of DWA2114R compared with CDDP and CBDCA could be due not only to the differences in carrier ligand structure but also to the properties of the whole molecule associated with the carrier ligand and leaving group.

Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation

Cisplatin, raceme-diaqua[1,2-bis(4-fluorophenyl)ethylenediamine]platinu m(II) sulfate (compound I), meso-diaqua[1,2-bis(4-fluorophenyl)ethylenediamine]-platinum(II) sulfate (compound II), and meso-diaqua[1,2-bis(2,6-dichloro-4- hydroxyphenyl)ethylenediamine]platinum(II) sulfate (compound III) were compared with regard to their effect on the MCF-7 breast cancer cell line in vitro. At equimolar concentrations (5 microM), cisplatin, compound I, and compound II were equiactive after 231 h drug exposure, whereas compound III was ineffective. Although compounds I and II showed markedly greater inactivation than did cisplatin after 6 h incubation with culture medium, compound I (but not compound II) exhibited antitumor activity equivalent to that of cisplatin when cells were exposed to the drugs for 6 h. Platinum measurements by neutron-activation analysis revealed that compound I was selectively and rapidly accumulated by MCF-7 cells, resulting in a high degree of DNA platination within the first few hours of drug exposure. However, when the drug-exposure period was long enough, platinum enrichment was not reflected in an overall difference in the cytotoxicity of compound I vs cisplatin. Nevertheless, compound I should be superior to cisplatin in vivo, provided that effective plasma levels can be maintained for about 6 h.

Synthesis, characterization, and antitumor activity of 1,2-bis(diphenylphosphino) ethane platinum(II) and palladium(II) complexes

A number of 1,2-bis(diphenylphosphino)ethane monomeric platinum(II) and palladium(II) complexes have been synthesized in light of their potential antitumor activity. The metal center is coordinated with a number of carboxylate anions in the cis-configuration. These complexes have been characterized by elemental analysis, conductivity measurement, and various spectroscopic techniques [IR and 195Pt NMR]. In vivo screening tests for activity of these complexes were performed against the L1210/0 murine leukemia cancer model, but none displayed a significant level of antitumor activity.

Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protection

Cisplatin is a chemotherapeutic coordination complex that has been evaluated extensively. It is particularly active against testicular cancer, but carcinomas of the ovary, bladder, cervix, and head and neck are also responsive. To increase efficacy and decrease toxicity, a number of platinum analogues have been developed and tested. One of these, carboplatin, is of particular interest. In clinical trials, it has demonstrated antitumor activity comparable to that of cisplatin, without evidence of significant renal toxicity or neurotoxicity. A second interesting platinum analogue is iproplatin. Preliminary phase I studies suggest reduced adverse renal and neurologic effects similar to those seen with carboplatin, with efficacy comparable to cisplatin. Attempts to overcome the dose-limiting toxicity of cisplatin by administering high-dose cisplatin (40 mg/m2/d for five days) in hypertonic saline or with thiosulfate protection are also reviewed. These techniques have eliminated nephrotoxicity as the dose-limiting toxicity of cisplatin. However, nonrenal toxicity, especially neurotoxicity, remains substantial. The extent to which high-dose cisplatin-based chemotherapy should be used in routine clinical practice has not been determined.

Ligands of second generation platinum analogs decrease both platinum-induced DNA cross-linking and its ability to interact with 1-beta-D-arabinofuranosyl cytosine to potentiate cytotoxic efficacy

We evaluated the cytotoxic and DNA cross-linking (CL) ability of four second generation platinum coordination complexes (TNO-6, JM-89, JM-8 and JM-9) delivered alone or in combination with 1-beta-D-arabinofuranosyl cytosine (ara-C) to human colon cancer cells (LoVo). Cell survival varied markedly as a function of the particular substitution moiety. JM-8 and JM-9 were virtually ineffective, even at concentrations as high as 50 micrograms/ml. At that concentration cis-diamminedichloroplatinum(II) (cis-DDP) killed greater than 99.99% of the cells. JM-82 was slightly more active while TNO-6 was the only derivative with appreciably higher cytotoxic activity due to an abrogation of the shoulder region of the type C survival curve. The highest CL effect was observed for cis-DDP followed closely by TNO-6. Very little CL effects were demonstrated for the other three analogs JM-82, JM-8 and JM-9 when measured 6 h after treatment. The combination of cis-DDP and ara-C augmented 10-fold the cytotoxic activity of cis-DDP alone, an effect accompanied by an almost 2-fold increase in CL; every other analog failed to interact in a potentiating manner (either cytotoxicity, or CL at 6 h) with the antimetabolite. Thus, it appears clear that the associated moieties of the Pt coordination complex play a fundamental role in reducing the interaction of the analogs with DNA (as reflected by the decreased CL and cytotoxic effects produced by each agent alone) and in totally preventing their interaction with ara-C to yield a potentiating lethal effect.